Systemic lupus erythematosus is a chronic, multisystem, inflammatory, autoimmune disorder characterized by formation of autoantibodies directed against self-antigens and immune-complex formation.
It can be suspected when ≥2 organ systems are involved.
It is predominantly diagnosed in females of childbearing age, rarely diagnosed before 8 years old.
Clinical presentation varies in different patients and the disease activity varies over time in a single patient. Majority of patients have arthralgia of the hand.
In systemic lupus erythematosus (SLE) patients treated with hydroxychloroquine (HCQ), longer duration of use and higher cumulative dose, as well as lower creatinine clearance and geographical origin from sub-Saharan Africa and West Indies, appear to be associated with an increased risk of treatment-related retinopathy, as reported in a study.
In the treatment of active systemic lupus erythematosus (SLE), early administration of belimumab especially in patients with low damage at baseline is likely to lead to remission and low-disease activity (LDA), according to real-world data.
The type I interferon receptor subunit 1 mAb* anifrolumab significantly improves response in patients with systemic lupus erythematosus (SLE) in the second phase III randomized trial of the drug, TULIP-2** — in contrast to the first trial.
Use of ustekinumab in the treatment of systemic lupus erythematosus leads to significant improvements in many of the efficacy indices evaluated, with lower risk of flares and sustained response rates, when compared with placebo, according to 1-year data from a phase II trial.
Among Filipino patients with systemic lupus erythematosus (SLE), the use of immunosuppressive and corticosteroid contributes to an increased risk of developing herpes zoster infection, a study has found. The risk is even higher in lupus nephritis patients exposed to intravenous cyclophosphamide and mycophenolate mofetil.
Belimumab for systemic lupus erythematosus (SLE) has demonstrated a stable safety profile over 8 years of follow-up, with no new safety signal and minimal organ damage progression, according to data from an extension study involving non-American patients who completed the phase III BLISS*-52 or BLISS-76 trials.
Belimumab treatment for systemic lupus erythematosus may induce low disease activity and clinical remission in patients with limited or no organ damage, as well as with positive antidouble stranded DNA titres, according to a study.
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Patients with psoriatic arthritis (PsA) often suffer from liver abnormalities, which are associated with higher body mass index (BMI), daily consumption of alcohol, more severe disease, and some therapies, according to a recent study.
Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.